NRX Pharmaceuticals
NRXP
33 hedge funds and large institutions have $3.44M invested in NRX Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 7 closing their positions.
602% more call options, than puts
Call options by funds: $358K | Put options by funds: $51K
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
13% more capital invested
Capital invested by funds: $3.04M → $3.44M (+$392K)
10% more funds holding
Funds holding: 30 → 33 (+3)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
0.15% less ownership
Funds ownership: 0.61% → 0.46% (-0.15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSA
HBK Sorce Advisory
Erie,
Pennsylvania
|
+$58.9K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$58.5K |
| 3 |
Charles Schwab
San Francisco,
California
|
+$44K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$35.7K |
| 5 |
AWM
AE Wealth Management
Topeka,
Kansas
|
+$29.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$885K |
| 2 |
BlackRock
New York
|
-$278K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$67.6K |
| 4 |
OCAM
Owl Creek Asset Management
New York
|
-$37K |
| 5 |
Goldman Sachs
New York
|
-$16K |
NRXP Hedge Fund Activity: Q4 2022 in Review
33 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q4 2022, worth a combined $3.44M — up 13% from $3.04M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new NRXP positions and 7 closed out — a net gain of 3 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was HBK Sorce Advisory, opening a new position worth an estimated $58.9K. The largest seller was JP Morgan Chase, cutting an estimated $885K.
- 33 institutional investors held NRX Pharmaceuticals (NRXP) as of Q4 2022, up from 30 in Q3 2022.
- Funds reported $3.44M of NRX Pharmaceuticals stock for Q4 2022, up 13% quarter-over-quarter.
- 10 funds opened new NRX Pharmaceuticals positions in Q4 2022 and 7 closed out, a net change of +3 holders.
- The largest NRX Pharmaceuticals buyer in Q4 2022 was HBK Sorce Advisory, an estimated $58.9K added.
- The largest NRX Pharmaceuticals seller in Q4 2022 was JP Morgan Chase, an estimated $885K sold.
Based on aggregated 13F filings for Q4 2022.